Head-To-Head Survey: Sartorius (SARTF) and The Competition

Sartorius (OTCMKTS:SARTF) is one of 142 public companies in the “MED INSTRUMENTS” industry, but how does it compare to its peers? We will compare Sartorius to related companies based on the strength of its institutional ownership, dividends, profitability, risk, earnings, analyst recommendations and valuation.

Earnings and Valuation

This table compares Sartorius and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sartorius	$3.66 billion	$90.90 million	130.94
Sartorius Competitors	$1.67 billion	$192.32 million	5.45

Sartorius has higher revenue, but lower earnings than its peers. Sartorius is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

54.1% of shares of all “MED INSTRUMENTS” companies are held by institutional investors. 14.8% of shares of all “MED INSTRUMENTS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sartorius and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sartorius	0	1	0	2	3.33
Sartorius Competitors	863	3505	6718	222	2.56

As a group, “MED INSTRUMENTS” companies have a potential upside of 34.12%. Given Sartorius’ peers higher probable upside, analysts plainly believe Sartorius has less favorable growth aspects than its peers.

Volatility and Risk

Sartorius has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Sartorius’ peers have a beta of 1.85, indicating that their average share price is 85% more volatile than the S&P 500.

Profitability

This table compares Sartorius and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sartorius	2.76%	7.62%	2.92%
Sartorius Competitors	-129.53%	-161.65%	-19.01%

Summary

Sartorius beats its peers on 7 of the 13 factors compared.

About Sartorius

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.